PUBLIC COMPANY
save$CLDXCelldex Therapeutics, Inc.
$CLDX41.92-0.07%Hampton, NJ, USupdated 11h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2A Study of Barzolvolimab in Patients With Prurigo Nodularis
- phase3A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
- phase3Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- phase1A Study of CDX-622 in Participants With Mild to Moderate Asthma
- phase1A Phase I Study of CDX-622
- phase2A Study of Barzolvolimab in Patients With Atopic Dermatitis
- phase3A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
- phase3A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
🐶 Hiring Signal
News
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…biopharma_dive · 26d ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that